Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Jul 9, 2026
- Accession no.
- 0001193125-26-299803
- Filed
- Jul 9, 2026, 4:54 PM ET
- Trade date
- Jul 8, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $784.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Common Stock | MOption exerciseAcquired | +32,375 | $6.38 | +$206,552.5 | 517,218 | Direct | |
| Jul 8, 2026 | Common Stock | SSaleDisposed | −32,375 | $24.24F2 | −$784,776.48 | 484,843 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Common Stock | MOption exerciseAcquired | +32,375 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $24.00 to $24.43
Referenced by the price of 1 transaction in Table I.